COMP <GO>
ZSTK vs HKPD // REVENUE GROWTH (YOY)
ZeroStack Corp. (NASDAQ) VS. Cellyan Biotechnology Co. Ltd (Class A) (NASDAQ) • 15-METRIC TALLY: ZSTK 2
— HKPD 0
■ METRIC PARITY
LAST: $2.93 (-0.34%) • MKT CAP: $63.9M
revenue-growth
-0.50%
LAST: $2.19 (+0.46%) • MKT CAP: $5.4M
revenue-growth
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ZSTK VS. HKPD)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ZSTK | HKPD | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 4.60% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -13.77% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | -0.50% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 46.2 | 35.5 | +10.68 | ZSTK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $63.9M | $5.4M | $58.5M | ZSTK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ZSTK REV | HKPD REV | ZSTK GROSS % | HKPD GROSS % | ZSTK FCF | HKPD FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $35.7M | — | 4.6% | — | -$8.8M | — |
| FY 2024 | $35.9M | — | 6.1% | — | -$5.2M | — |
| FY 2023 | $76.1M | — | — | — | -$8.4M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ZSTK // BETA —
HKPD // BETA —